Did You Suffer Losses Investing in CVRx (CVRX)?

On November 9, 2026, a securities class action complaint was filed against CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX) on behalf of persons and entities that purchased shares of CVRx common stock between July 25, 2023 and August 6, 2026, inclusive (the “Class Period”). 

The action, Oklahoma Police Pension and Retirement System v. CVRx, Inc., et al., was filed in the United States District Court for the District of Minnesota and asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

CVRx Securities Class Action Allegations

According to the complaint, defendants made materially false and/or misleading statements concerning CVRx’s financial results, business, operations, and compliance policies. The challenged statements concerned alleged illegal and unsustainable sales practices involving CVRX’s Barostim medical device, including improper marketing, offering or paying kickbacks, and providing false information to government health insurance programs in violation of the False Claims Act and Anti-Kickback Statute. The complaint further asserts that revenues were, in part, the product of such conduct and therefore unsustainable, and that the practices increased the risk of criminal and civil liability.

The complaint also challenges defendants’ statements about CVRx’s sales force realignment and commercial transformation. It asserts that turnover had not stabilized; productivity remained materially below expectations because the sales organization required additional training, support, and restructuring; and a significant portion of the sales force was inexperienced, required extended training and ramp time, and was not yet capable of generating the productivity needed to meet revenue projections.

CVRx Discloses DOJ Investigation and Cuts Outlook; Shares Decline

On August 6, 2026, after the market closed, CVRx filed a Form 10-Q disclosing that it had received a civil investigative demand from the U.S. Department of Justice on May 14, 2026, in connection with a False Claims Act investigation. The demand sought information concerning whether CVRx caused false claims to be submitted to government health insurance programs through improper device marketing, kickbacks to healthcare providers, or false information provided to those programs. The investigation does not establish that CVRx violated the law.

Also on August 6, 2026, CVRx reduced its outlook, citing, in part, weak sales force productivity. The Company disclosed that approximately 60% of its quota-carrying territory managers had joined during the preceding 18 months, straining onboarding and training processes, and identified sales force turnover and the slower pace at which new territory managers were becoming productive as primary factors behind the guidance update.

Following these disclosures, CVRx common stock declined $3.55 per share, or approximately 60%, from $5.94 per share on August 6, 2026 to close at $2.39 per share on August 7, 2026.

January 8, 2027 Lead Plaintiff Deadline

CVRx investors have until January 8, 2027 to move the Court for appointment as lead plaintiff. Investors do not need to seek appointment as lead plaintiff to remain a member of the proposed class.